secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001493152-23-000622
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Bioscience enters exclusive distribution agreement with Ming Mei Technology for Taiwan
--------------------------------------------------------------------------------

- Exclusive distributor for Taiwan with initial 1-year term, renewable automatically.
- Ming Mei estimates ~90% coverage of reagents and consumables in Taiwan's reproductive medicine market.
- Planned introduction of INVOcell in early 2023; Taiwan had ~55,000 ART cases in 2019.
- CEO cites decreasing birth rates and rising treatment costs as market drivers.
- Agreement includes exclusive rights to INVO trademarks in Taiwan for product sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000149315223000622/0001493152-23-000622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000149315223000622/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-000622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer